Suppr超能文献

二价铁制剂和三价铁制剂的生物利用度及治疗效果

Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations.

作者信息

Kaltwasser J P, Werner E, Niechzial M

出版信息

Arzneimittelforschung. 1987 Jan;37(1A):122-9.

PMID:3566867
Abstract

The bioavailability of iron on Fe(III)-hydroxide-polymaltose complex was compared intraindividually with that of Fe (II)-ascorbate (iron absorption) and a Fe (II)-sulphate quick release preparation (haemoglobin regeneration test). The study was carried out in a population of 16 healthy male volunteers, phlebotomized in weekly intervals until development of an iron deficiency anaemia in order to establish a test population with only small variations of their individual body iron status. Intestinal iron absorption in fasting state as measured by 59Fe whole body retention and simultaneous estimation from plasma iron tolerance curves was low for the 59Fe (III)-complex (1.2 +/- 0.1% (means +/- SD] as compared to the 59Fe (II)-ascorbate (43.7 +/- 7.1% (means +/- SD]. Iron administration together with a test meal did not affect the absorption from the 59Fe (II)-ascorbate, whereas the 59Fe (III)-complex showed a significant increase in absorption (8.8 +/- 4.7% (means +/- SD]. Haemoglobin (Hb) regeneration after 100 mg of iron as Fe (III)-complex and Fe (II)-sulphate administered during 28 days with meals amounted to a mean of 0.68 +/- 0.2 g/l and 1.1 +/- 0.3 g/l (means +/- SD) of total daily Hb-increase and a net-Hb-increase of 0.31 +/- 0.37 g/l and 0.79 +/- 0.36 g/l (means +/- SD), respectively. There was also a small but significant rise in serum ferritin during the oral treatment in both treatment groups. The results of Hb-regeneration after treatment with the Fe (III)-complex were in the range which could be expected from the absorption measurements.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

将氢氧化铁-聚麦芽糖复合物中铁的生物利用度与抗坏血酸亚铁(铁吸收)和硫酸亚铁速释制剂(血红蛋白再生试验)在个体内进行了比较。该研究在16名健康男性志愿者群体中进行,每周进行一次静脉放血,直至出现缺铁性贫血,以便建立一个个体身体铁状态差异较小的测试群体。通过59Fe全身保留量以及从血浆铁耐受曲线同时估算,在禁食状态下,59Fe(III)复合物的肠道铁吸收较低(1.2±0.1%(均值±标准差)),而59Fe(II)-抗坏血酸为43.7±7.1%(均值±标准差)。与测试餐一起服用铁剂对59Fe(II)-抗坏血酸的吸收没有影响,而59Fe(III)复合物的吸收则显著增加(8.8±4.7%(均值±标准差))。在28天内随餐服用100 mg铁(以Fe(III)复合物和硫酸亚铁形式)后,血红蛋白(Hb)再生量分别为每日总Hb增加量平均0.68±0.2 g/l和1.1±0.3 g/l(均值±标准差),净Hb增加量分别为0.31±0.37 g/l和0.79±0.36 g/l(均值±标准差)。两个治疗组在口服治疗期间血清铁蛋白也有小幅但显著的升高。用Fe(III)复合物治疗后的Hb再生结果在吸收测量所预期的范围内。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验